Latest news and press releases about MAIA Biotechnology, Inc. (MAIA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Price
| Price | $1.40 |
| Market Cap | $85M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 4.15 |
| EV / EBITDA | -3.11 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -211.15% |
| Return on Invested Capital | -131.68% |
| Return on Assets | -95.06% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · PYPD
Explore sector: Healthcare · Biotechnology
More sections of MAIA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks